SCHEMBL13329339

SCHEMBL13329339

Cc1nc2c(c(=O)n1C1c3ccccc3-c3ccccc31)CN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
MAPT P10636 2/20 0.42
PDE10A Q9Y233 1/20 0.40
DDB1 Q16531 2/20 0.39
CRBN Q96SW2 2/20 0.39
C5AR1 P21730 2/20 0.39
PDK4 Q16654 1/20 0.39
F12 P00748 1/20 0.39
MTOR P42345 2/20 0.39
UCHL1 P09936 1/20 0.38
MTHFD2 P13995 1/20 0.38
P2RX3 P56373 2/20 0.38
ESR2 Q92731 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OGFRL1 Q5TC84 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249968 0.92 PARP1 (0.51) PARP1TNKS2PARP2MAPTDDB1
SCHEMBL2456692 0.77 MAPT (0.46) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL13250011 0.77 PARP1 (0.45) PARP1TNKS2PARP2MAPTDDB1
SCHEMBL13328836 0.77 MAPT (0.43) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL3106590 0.73 C5AR1 (0.44) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL14328064 0.72 P2RX7 (0.49) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL13328818 0.72 PRLHR (0.42) MAPT
SCHEMBL26703566 0.72 PRLHR (0.46) MAPTP2RX3ESR2
SCHEMBL13328873 0.71 MAPT (0.40) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL3301786 0.71 MGAT2 (0.49) PARP1TNKS2PARP2MAPTPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GPR180, GPR17 PARP1 971/4885TNKS2 1527/4885PARP2 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.